Novo Nordisk’s Sickle Cell Success Charts a New Path Beyond Blockbuster Drugs
Novo Nordisk’s etavopivat reduces sickle cell crises by 27% in Phase 3 trial, marking a key diversification move…
Novo Nordisk’s Sickle Cell Success Charts a New Path Beyond Blockbuster Drugs
Novo Nordisk’s etavopivat reduces sickle cell crises by 27% in Phase 3 trial, marking a key diversification move…
Energy Transition Minerals faces likely licence renewal rejection for Greenland project
Greenland has informed Energy Transition Minerals of a potential rejection of its exploration licence renewal application for the…
Novo Nordisk Charts a New Strategic Direction Amid Challenges
Novo Nordisk navigates FDA warnings, partners with Hims & Hers for digital sales, and expands in South America…
Novo Nordisk Charts Long-Term Course with Major Irish Facility Investment
Novo Nordisk commits over €400M to expand Irish tablet plant for diabetes & obesity drugs, signaling long-term strategy…
Novo Nordisk Charts a New Strategic Course Amid Market Shifts
Novo Nordisk cuts Wegovy & Ozempic prices by 50%, partners on $2.1B oral drug deal, and faces a…